The company should revive from the regulatory setback

It has been a rough ride for pharma stocks over the last couple of years, thanks to the increased regulatory activism, particularly in the US. While the regulatory issues facing Indian companies have been a sentiment dampener, these need to be viewed in the light of the company’s ability to ensure compliance and the growth opportunity over the medium to long term. Regulatory overhangThe knee je...